Article Text

Download PDFPDF
Sensitivity and specificity of optical spectral transmission imaging in detecting joint inflammation in rheumatoid arthritis
  1. Simon Krabbe1,
  2. Mads Ammitzbøll-Danielsen1,2,
  3. Mikkel Østergaard1,2,
  4. Marie-Claude Giard1,3,
  5. Lene Terslev1
  1. 1Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet-Glostrup, Glostrup, Denmark
  2. 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
  3. 3Rheumatology Department, Verdun Hospital, Montreal, Canada
  1. Correspondence to Lene Terslev, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet-Glostrup, Nordre Ringvej 57, Glostrup DK-2600, Denmark; terslev{at}dadlnet.dk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Optical spectral transmission imaging (OI) measures the blood-specific absorption of light transmitted through tissue.1–5 OI of joints may measure the level of inflammation in joint diseases such as rheumatoid arthritis (RA), where the inflammatory process is associated with angiogenesis and increased blood flow.

We compared OI by Hemics Full Hand Proto with colour Doppler (CD) ultrasonography as gold standard reference for inflammation. Sixty-two patients fulfilling the 2010 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria for RA, with no significant deformation of hands or wrists and no surgery for the last 3 months, had OI performed of the wrists and all metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints. Median age was 62 years, 76% were female, median DAS28 was 3.6 and 71% were anti-CCP-positive. Fifty-eight received disease-modifying antirheumatic drugs (synthetic, biological or in combination), five of these in combination with prednisolone. Four patients did not receive antirheumatic treatment. An OI score of …

View Full Text

Footnotes

  • Contributors LT and MØ conceived of the study. SK analysed data and drafted the letter. All authors discussed the data and contributed to and approved the final version.

  • Funding Hemics provided the Hemics Full Hand Proto scanner.

  • Competing interests None declared.

  • Ethics approval The study was approved by Ethics Committee, Region Hovedstaden, Denmark.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Data may be shared after agreement with LT and MØ.

Linked Articles